Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Pathways (CLPA) -- Ignore unavailable to you. Want to Upgrade?

To: bob who wrote (59)	12/13/1998 7:05:00 PM
From: Epicenter	Read Replies (1) \| Respond to of 566

Bob: Currently I am not a shareholder although I was tempted to buy after their presentation at the RobertsonStevens meeting a week ago. At that time, they said that the data will be published in a peer-reviewed journal like Science/Nature but didn't mention anything about the patent disclosure (I guess they couldn't). When I talked to the CEO and one other at that meeting, they sounded pretty decent. The My honest opinion is that they may be on to something but from the scientific viewpoint, I am not sure. If it is a PDE inhibitor, what about concerns about toxicity, particularly in a chronic, preventive treatment? I doubt the enzyme is tissue specific so we need to watch out. It better be extremely safe. I'll probably hear from them at the Furman Selz meeting this week and then I'll decide what to do. Of course, if the stock skyrockets, shorting it may not be that unreasonable (just like Geron and Entremed in the past). Just a thought. Epicenter